As oncology contemplates the potential impact of a second Donald Trump term on cancer care and research, The Cancer Letter has compiled a list of guest editorials, news analyses, and data-driven reports that this magazine published during his first term. Days after the 2016 election, there were uncertainties about President Barack Obama’s signature healthcare programs—the […]
Drs Camidge and McLaren discuss Dr McLaren’s journey to medical school and his experience as a clinical oncologist with expertise across disciplines.
Lactylation, a recently identified post-translational modification, has initially been linked to gene transcription regulation through epigenetic mechanisms. However, its role in tumorigenesis—whether as a major…
Study authors said toripalimab plus chemotherapy could be a first-line treatment option, but authors of a related commentary said a global study may be needed…
A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from multiple TROPION trials, following FDA feedback.
An abstract is unavailable.
Five-fraction SBRT was noninferior to radiotherapy in a phase 3 trial of patients with low- to intermediate-risk localized prostate cancer.
Kari Wisinski, MD, discusses factors that influence her decision between CDK4/6 inhibitors for patients with treatment-naive, HR+ metastatic breast cancer.
Anna Weiss, MD, discusses the significance of various imaging modalities in patients with breast cancer.
Roy S. Herbst, MD, PhD, discusses advances in EGFR inhibition throughout the past several decades in patients with lung cancer.
First generation Bruton’s tyrosine kinase (Btk) inhibitors were associated with both decreased thrombosis and increased bleeding. However, newer more selec
